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Abstract  
Background/Aims: Inflammation and endothelial dysfunction contribute to cardiovascular disease, 
prevalent in CKD. Antioxidant supplements such as tocopherols may reduce inflammation and 
atherosclerosis. This study aimed to investigate the effect of tocopherol supplementation on vascular 
function, aortic plaque formation and inflammation in apolipoprotein E
-
/
-
 mice with 5/6 nephrectomy as 
a model of combined cardiovascular and kidney disease. Methods: Nephrectomised mice were 
assigned to a normal chow diet group (normal chow), a group receiving 1000 mg/kg diet of α-
tocopherol supplementation or a group receiving 1000 mg/kg diet mixed tocopherol (60% γ-
tocopherol). Results: Following 12-weeks, in vitro aortic endothelial independent relaxation was 
enhanced with both α-tocopherol and mixed tocopherol (p<0.05) while mixed tocopherol enhanced 
aortic contraction at noradrenaline concentrations of concentrations 3x10
-7 
M to 3x10
-5
 M
 
(p<0.05), 
when compared to normal chow. Supplementation with α- and mixed-tocopherol reduced systemic 
concentrations of IL-6 (p<0.001 and p<0.001, respectively) and IL-10 (p<0.05 and p<0.001, 
respectively) while α-tocopherol also reduced MCP-1 (p<0.05) and TNF-α (p<0.05). Aortic sinus 
plaque area was significantly reduced with α-tocopherol supplementation when compared to normal 
chow (p<0.01). Conclusion: Tocopherol supplementation favourably influenced vascular function and 
cytokine profile while it was also effective in reducing atherosclerosis in the apolipoprotein E
-
/
-
 mouse 
with CKD.   
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Introduction 
Chronic kidney disease (CKD) is associated with increased cardiovascular morbidity and mortality 
[1, 2]. Elevated levels of oxidative stress, inflammation and endothelial dysfunction are believed to 
contribute to the development of cardiovascular disease, which begins in the early stages of CKD 
[3, 4]. Strategies targeted at reducing oxidative stress, inflammation and endothelial dysfunction 
may provide effective treatment in the early stages of CKD, with the potential to slow the decline in 
kidney function and associated cardiovascular disease.   
 
Evidence suggests antioxidant supplements such as tocopherols (vitamin E) reduce oxidative stress 
and inflammation. Tocopherol supplementation (α and γ isoforms) has recently been shown to lower 
levels of inflammatory C-reactive protein, a predictor of morbidity and cardiovascular events among 
CKD patients [5],  and lipid oxidation marker F2 isoprostanes in patients with cardiovascular disease 
[6].  Fourteen days of γ-tocopherol supplementation in haemodialysis patients has been associated 
with a reduction in C-reactive protein. However, α-tocopherol supplementation was shown to have no 
significant effect [7, 8]. In vitro, physiological concentrations of γ-tocopherol block the synthesis of 
prostaglandin E2 by murine macrophages and human epithelial cells [9]. In contrast, α-tocopherol had 
no effect on the synthesis of these inflammatory mediators [9, 10]. These effects of γ-tocopherol may 
be significant because arachidonic acid metabolites such as prostaglandin E2 and leukotriene B4 are 
implicated in the development of atherosclerosis [11].  
 
What may prove effective treatment to reduce atherosclerosis in models of cardiovascular disease 
alone may not be as effective in CKD where atherosclerosis is exacerbated, possibly due to non-
traditional risk factors underlying disturbances in calcium and phosphate, inflammation and oxidative 
stress. -tocopherol was beneficial in reducing cardiovascular disease end-points in dialysis patients 
[12] and those with established atherosclerosis [13]. However, other large scale trials have shown no 
effect on cardiovascular outcomes in high risk cardiovascular patients and those post-myocardial 
infarction [14, 15]. These differences may in part be attributable to different stages of kidney disease, 
varying levels of established cardiovascular disease, length of follow-up period and the source of 
vitamin E supplementation (eg. concentrated α-tocopherol versus naturally occurring dietary vitamin 
E). Investigating the impact of different tocopherols on the progression of atherosclerosis in CKD 
without other treatments may lead to a greater clinical understanding of the disease process and 
translation to potential therapeutic targets. 
 
Elevated levels of inflammation and oxidative stress are associated with the severity of CKD and 
accelerated progression of cardiovascular disease in CKD patients. The effectiveness of the anti-
inflammatory properties of antioxidant supplements for reducing markers of inflammation and 
atherosclerosis in early stage CKD patients is yet to be explored. The aim of the present study was 
to determine the influence of α-tocopherol and mixed-tocopherol (high in γ-tocopherol) 
supplementation on the development of atherosclerosis, endothelial dysfunction and inflammation in 
apoE
-
/
-
 mice with 5/6 nephrectomy. 
 
  
  
Methods 
Animals and Diet 
Ten-week-old male apoE
-
/
-
 mice (B6.129P2-Apoe 
tm1Unc
/Arc, Animal Resource Centre, Canning Vale, 
Western Australia) underwent 5/6 nephrectomies. One week following surgery mice were allocated to 
one of the following groups: 1) 5/6 nephrectomy (Nx) (n=10), 2) 5/6 nephrectomy fed α -tocopherol at 
1000 mg per kg diet (α -tocopherol) (n=10) and 3) 5/6 nephrectomy fed mixed tocopherol diet 
including 60% γ-tocopherol, 14% α-tocopherol, 2% β-tocopherol and 24% δ-tocopherol at 1000 mg/kg 
diet (mixed-tocopherol) (n=10). Mice were housed in separate cages (46 x 26 x 14.5 cm) and 
maintained on a 12-hour light/dark photo-period with a room temperature of 21 ± 2ºC. All mice were 
fed standard mouse chow and water ad libitum. The institutional Animal Ethics Committee in 
accordance with the Australian Code of Practice approved all procedures for the Care and Use of 
Animals for the Scientific Purposes. 
 
Surgical Procedures 
CKD was induced by 5/6 nephrectomy where the right kidney was removed and the lower branch of 
the left renal artery was ligated to produce approximately two thirds area with renal ischemia. To 
ensure uniform kidney damage, an angled point cautery was applied to the fully exteriorized left 
kidney cortex [16]. Anaesthesia was induced with Isoflurane mixed with oxygen delivered using a 
precision vaporizer. Buprenorphine was given for analgesia after surgery at a dose of 0.05 mg/kg 
subcutaneously every 3-5 hours for up to 24 hours. 
 
Anaesthesia 
After 12-weeks mice were exsanguinated following the administration of 90 mg/kg pentobarbital 
sodium (Nembutal) via an intraperitoneal injection. Anaesthesia was monitored prior to opening the 
chest wall by testing for the presence of reflexes. Blood was collected by the insertion of a 25-gauge 
syringe into the vena cava. The heart was then removed and placed in 10% buffered formalin 
solution.   
 
Vascular function 
Immediately after exsanguination, the thoracic aorta was removed and dissected into three 3-mm 
aortic rings to be suspended and hooked to a force transducer in a warmed organ bath (37 ± 0.5ºC) 
containing gassed (95% O2 and 5% CO2) physiological solution. Smooth muscle cell contractile 
function was determined by a cumulative concentration-response curve to increasing concentrations 
of noradrenaline (concentration 10
−9
 to 10
−5
 M). Endothelial control of vascular relaxation 
(endothelium-dependent) was determined by the addition of muscarinic agonist acetylcholine 
(concentration 10
−9
 to 10
−5
 M) following a 70% submaximal pre-contraction to noradrenaline. Smooth 
muscle cell vasorelaxant function (endothelium-independent relaxation) was assessed by the addition 
of sodium nitroprusside (concentration 10
−9
 to 10
−5
 M) following pre-contraction with noradrenaline. 
The change in isometric force was measured by Grass FT03 force transducers (Grass, MA, USA) 
connected to a PowerLab chart recording system using Chart 4.0 recording software (AD Instruments, 
Sydney, NSW, Australia).  
 
Cytokine Determination 
The plasma concentrations of interleukin (IL)-6, IL-10, monocyte chemotactic protein (MCP)-1, 
macrophage inflammatory protein (MIP)-1α, KC and tumour necrosis factor (TNF)-α were assayed 
simultaneously using the multiplex assay technique in a suspension array system according to the 
manufacturer’s instructions (Mouse Cytokine/Chemokine LINCOplex KIT, LINCO Research Inc., St. 
Charles, MO, USA). 
 
  
  
Plaque Formation 
The heart, including the aortic root, was removed and fixed in 10% buffered formalin
 
for measurement 
of the surface area covered by lipid-staining
 
lesions. The aortic root was cross-sectioned serially with 
10 by 10 µm thick slices taken 80 µm apart, stained for oil red O and evaluated microscopically using 
the Scanscope Imagescope system (Aperio Technologies, Vista, CA, USA). 
 
Statistical Analyses 
Data were first tested for normality and non-normally distributed data were log transformed prior to 
analysis. To determine differences in vascular function between groups a two way ANOVA (group x 
drug concentration) was performed. To determine differences between groups in other variables a 
one-way ANOVA was performed. Where a main interaction (group x drug concentration) or a main 
effect of group was found, post hoc testing was performed comparing the α- and mixed-tocopherol 
groups to the nephrectomy group with a Bonferroni correction. Significance was set at p<0.05. Data 
were analysed using Prism 5 for Windows (GraphPad Software, Inc., CA, USA). Data are presented 
as mean ± SD unless otherwise indicated. 
 
  
  
Experimental Results 
Creatinine 
Creatinine concentrations were not significantly different between α-tocopherol (219 ± 77 µmol/L), 
mixed-tocopherol (243 ± 70 µmol/L) or Nx (243 ± 70 µmol/L) (p=0.69). 
 
Body Mass 
At 12-weeks, the body mass of α-tocopherol (27.9 ± 1.9 g), mixed-tocopherol (27.7 ± 1.2 g)  and Nx 
(27.4 ± 1.7 g) mice was not significantly different (p=0.79).  
 
Vascular Function 
There was a significant interaction of group and drug concentration for noradrenaline induced aortic 
vasoconstriction (p<0.0001). Mixed-tocopherol supplementation significantly enhanced 
vasoconstriction in response to noradrenaline when compared to Nx at concentrations 3 x 10
-7 
M to 3 
x 10
-5
 M
 
(p<0.05) (Figure 1A). Both endothelium-dependent and endothelium-independent relaxations 
were significantly different between groups and drug dose (p<0.0001). At an acetylcholine 
concentration of 1 x 10
-5 
M, mixed-tocopherol was significantly greater than Nx (p <0.05) (Figure 1B). 
α-tocopherol and mixed-tocopherol significantly enhanced endothelial-independent vascular 
relaxation when compared to Nx (p<0.05) (Figure 1C). 
 
Total Plaque Area 
Plaque area was significantly different between groups (p=0.007). -tocopherol significantly reduced 
plaque area when compared to standard chow (p<0.01) (Figure 2). 
 
Cytokines 
There was a significant difference between groups for IL-6 (p=0.003), IL-10 (p=0.008), MCP-1 
(p=0.029) and TNF-α (p = 0.036) concentrations (Figure 3). Supplementation with α- and mixed-
tocopherol reduced systemic concentrations of IL-6 (p<0.001 and p<0.001, respectively) and IL-10 
(p<0.05 and p<0.001, respectively), while alpha tocopherol also reduced MCP-1 (p<0.05) and TNF- α 
(p<0.05). There was no effect of supplementation on MIP-1α (p=0.782) or KC (p=0.364). 
 
Discussion 
Knowledge relating to the effectiveness of various tocopherols on the progression of cardiovascular 
disease in the presence CKD is limited. The current study demonstrates that in a mouse model of 
combined cardiovascular disease and CKD, α- and mixed-tocopherol supplementation favourably 
influenced thoracic aortic vascular function, while α-tocopherol supplementation was also effective in 
reducing aortic sinus plaque area. The improved vascular function following tocopherol 
supplementation and the reduction in plaque area following α-tocopherol supplementation were 
associated with reductions in circulating inflammatory cytokine concentrations. -tocopherol appears 
superior to mixed-tocopherol for reducing atherosclerosis in a model of combined CKD and 
cardiovascular disease. 
 
Inducing CKD in apoE
-
/
-
 mice increases plaque formation [17], indicating that kidney dysfunction is 
associated with the presence of atherosclerosis. In the present study, supplementing CKD apoE
-
/
- 
mice with α-tocopherol significantly reduced plaque area in the aortic sinus. In apoE
-
/
-
 mice without 
CKD, six weeks of α-tocopherol supplementation at 800 mg/kg diet has been shown to reduce aortic 
lesion area by 55%, despite no reduction in serum cholesterol or improvements in lipoprotein profile 
[18]. In another study, apoE
-
/
- 
mice on an atherogenic diet supplemented with 400 mg of α-
tocopherol/kg diet had a reduction in the proportion of advanced aortic lesions compared to control 
apoE
-
/
- 
mice [19]. One study in metabolic syndrome patients investigated the effects on α-, γ- or 
combined-tocopherol supplementation and suggested that a combination was superior in reducing 
inflammatory marker CRP [20]. However, to date there are no published studies comparing the effects 
  
of α- and mixed-tocopherol supplementation of cardiovascular disease markers in the one study 
Dietary supplementation with α-tocopherol attenuates the circulating concentrations of γ-tocopherol 
and δ-tocopherol in humans [21]. This effect occurs as a result of increased metabolism of γ-
tocopherol, and competition between α-tocopherol and γ-tocopherol for transport proteins within the 
intestine [22]. Considering the greater biological activity of γ-tocopherol, suppression of γ-tocopherol 
may potentially increase the risk of atherosclerosis, although in the present while plasma 
concentrations of tocopherol were not measured, mixed-tocopherol supplementation did not 
significantly reduce plaque area.  
 
 
Plaque reductions following α-tocopherol supplementation have been associated with reduced 
expression of MCP-1 in aortic lesions [18] and indeed in the present study we found a reduction in 
circulating concentration of MCP-1 with α-tocopherol but not mixed-tocopherol supplementation. Pro-
inflammatory cytokines also stimulate increased endothelial cell expression of adhesion molecules, 
including ICAM-1 which has been correlated with atherosclerosis [23] and is elevated in CKD patients 
when compared to healthy controls [24]. Tocopherol given to rabbits (dominant in α-tocopherol) 
reduces plaque deposits and reduces aortic ICAM-1 expression [25]. In human endothelial cell 
cultures, α-tocopherol reduced the production of IL-1beta stimulated MCP-1, IL-8, IL-6 production and 
ICAM-1 expression [26]. γ-tocopherol has an opposing effect, increasing ICAM-1 [27] which may 
explain the lack of effectiveness of mixed-tocopherol, high in γ-tocopherol, for reducing aortic plaque 
area in the present study. TNF-α concentration, which may also induce ICAM-1, was significantly 
reduced in mice supplemented with α-tocopherol but not mixed-tocopherol. IL-6 and IL-10 were 
significantly reduced with both α- and mixed-tocopherol, whereas α-tocopherol also reduced MCP-1 
and TNF-α. Our findings suggest that α-tocopherol is effective at reducing inflammation associated 
with atherosclerosis in the presence of CKD. 
 
The increased burden of cardiovascular disease in the presence of CKD has been attributed to non-
traditional risk factors underlying disturbances in calcium and phosphate, inflammation and 
oxidative stress [2-4] that have all been shown to impair vascular function, which often precedes 
formation of atherosclerosis. In cardiovascular disease alone hypertension has been related to 
atherosclerosis development however, blood pressure in the apoE
-
/
-  
mouse is unaffected by CKD 
[16, 28] and as such unlikely to contribute to vascular dysfunction. Previous studies have reported 
vascular dysfunction in uremic apoE
-
/
- 
mice fed a Western diet,[29] whereas endothelial dysfunction 
was not present in plaque free aorta segments in non-uremic apoE
-
/
- 
mice fed standard chow [30]. 
Mixed- and α-tocopoherol supplementation enhanced maximal endothelial-independent aortic 
relaxation. Endothelial dysfunction in CKD rats has been attributed to a decrease in nitric oxide 
production and an increase in reactive oxygen species [31]. γ- and α-tocopherol supplementation 
have been shown to reduce ex-vivo LDL oxidation and increase SOD activity in rats, with a more 
potent effect of γ-tocopherol which also increased constitutive nitric oxide synthase [32]. The 
increase in aortic contraction seen in the mixed tocopherol group (60%γ-tocopherol) may possibly 
be due to increased H2O2, produced from conversion of superoxide by elevated SOD, which is 
recognized as an endothelium derived contracting factor [33]. Increased endothelial-independent 
relaxation may also be related to increased SOD activity that has been associated with greater 
endothelial-independent relaxation in the diabetic rat [34].  
 
In this model of combined CKD and cardiovascular disease, supplementation with α-tocopherol for 
12-weeks was effective in reducing plaque area. Reducing plaque formation and improving vascular 
function may influence cardiovascular morbidity and mortality. Future work should determine the 
effect of tocopherol supplementation on the progression of both cardiovascular disease and renal 
dysfunction in patients with CKD. 
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Figure Legends 
 
Figure 1. A. Aortic smooth muscle contraction with noradrenaline (NA) dose response curve, * = 
significantly different from Nephrectomy (NX) Nx and -tocopherol (alpha). B. Endothelial-dependent 
relaxation with acetylcholine (Ach) dose response curve. C. Endothelial-independent sodium 
nitroprusside (SNP) relaxation dose response curve, * = significantly different from Nx. Data are mean 
± SE. *= significantly different from Nx (p<0.05). 
 
Figure 2. Total plaque area over 180 um with representative images of aortic sinus stained with Oil 
Red O (depicted as darker areas). Nx=sedentary nephrectomy and standard diet, alpha=nephrectomy 
and α-tocopherol supplementation, mixed=nephrectomy and mixed tocopherol (including 60% γ-
tocopherol, 14% α-tocopherol, 2% β-tocopherol and 24% δ-tocopherol ) supplementation. Data are 
mean ±SE. *= significantly different from Nx (p<0.05). 
 
Figure 3. Plasma cytokine concentrations following 12 weeks of α-tocopherol supplementation or 
mixed tocopherol supplementation, or standard diet. Data are mean ±SE. Nx= nephrectomy and 
standard diet, alpha=nephrectomy and α-tocopherol supplementation, mixed=nephrectomy and mixed 
tocopherol (including 60% γ-tocopherol, 14% α-tocopherol, 2% β-tocopherol and 24% δ-tocopherol ) 
supplementation. *= significantly different from Nx (p<0.05). 
 
 
 
 
 
 
